RJFSA
CTXR icon

Raymond James Financial Services Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-444
Closed -$9.96K – 3435
2024
Q1 		$9.96K Hold
444
– – ﹤0.01% 3365
2023
Q4 		$8.4K Hold
444
– – ﹤0.01% 3270
2023
Q3 		$7.6K Hold
444
– – ﹤0.01% 3239
2023
Q2 		$13.3K Hold
444
– – ﹤0.01% 3201
2023
Q1 		$13K Hold
444
– – ﹤0.01% 3210
2022
Q4 		$8.77K Hold
444
– – ﹤0.01% 3200
2022
Q3 		$13K Buy
+444
New +$12.2K ﹤0.01% 3194

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial Services Advisors's CTXR Position: Q2 2024 in Review

Raymond James Financial Services Advisors sold out of Citius Pharmaceuticals (CTXR) in Q2 2024, closing a stake of 444 shares — an estimated $9.96K sold.

Raymond James Financial Services Advisors first reported a position in CTXR in Q3 2022 and held it in 7 quarters. The position peaked at $13.3K in Q2 2023. 72 funds tracked by Wall St. Rank hold CTXR as of Q2 2024.

  • Raymond James Financial Services Advisors reported no remaining Citius Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 444 Citius Pharmaceuticals shares in Q2 2024, an estimated $9.96K.
  • Raymond James Financial Services Advisors first reported a position in Citius Pharmaceuticals in Q3 2022 and held it in 7 quarters.
  • Raymond James Financial Services Advisors's Citius Pharmaceuticals position peaked at $13.3K in Q2 2023.
  • 72 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2024, filed 19 Jul 2024.